US Benign Prostatic Hyperplasia

US Benign Prostatic Hyperplasia (BPH) Procedures
to Grow at a CAGR of 4.2% by 2023
[email protected]
US Benign Prostatic Hyperplasia (BPH)
Increase in the aging population in the U.S in the next few years, is expected to create high
demand for BPH treatments, since the population aged 50 years and above is more prone to
BPH, and therefore tend to opt for various treatments that involve the use of procedures such as
TURP, TUIP and laser based treatments. According to the National Institute of Health, it has been
estimated that around 14 million men in the U.S. had symptoms suggestive of BPH, which can
affect 50% of men aged between 51 and 60 years of age, and up to 90% of men aged more than
80 years. With 50% of men getting affected with BPH, there is a consequent increase in the BPH
The advanced research and development activities has led to the development of
technologically advanced BPH devices and therapies. Prostatic urethral lift (Urolift system) and
targeted sterile water vapor therapy (Rezūm) are some of the recent technological therapies
launched for BPH management. Rezūm is a minimally invasive procedure that uses steam in the
treatment of enlarged prostate and is currently available in the U.S. These therapies can be
performed in a clinic or at an outpatient facility, and thereby reduce the cost associated with
hospital stay and surgeries.
Access Detailed Report Summary on "US Benign Prostatic Hyperplasia (BPH) Procedures" at:
Access Detailed Report Summary on "Global Benign Prostatic Hyperplasia (BPH) Procedures" at:
US Benign Prostatic Hyperplasia (BPH)
Insights on market segments
As per the findings of the research, the different type of BPH treatment
procedure include laser based procedures, surgical procedures, UroLift and
other energy based procedures. Laser based procedures is expected to
account for the largest share in the U.S. BPH procedures during the forecast
period, since these procedures are more effective, as compared to the
conventional procedures and are less likely to cause bleeding and other
complications. Urolift is projected to register the fastest growth during the
forecast period, mainly driven by the aging U.S. population, expanding
insurance coverage of the procedure by various insurers, low cost of the
procedure, and possibility of indication expansion of the UroLift procedure
for the treatment of patients with BPH who have an obstructive median
US Benign Prostatic Hyperplasia (BPH)
Key players are acquiring other players in the U.S.
BPH procedures
Key player in the U.S. BPH procedures are acquiring other players to offer
advanced products for BPH treatment procedures. For instance, in
September 2017, Teleflex Incorporated, announced that the company has
entered into definitive agreement with NeoTract, Inc. Under the terms of
the agreement, Teleflex Incorporated agreed to acquire NeoTract, Inc. for a
consideration of up to $1.1 billion. With this agreement, Teleflex
Incorporated would be able to leverage the potential long-term benefits
from NeoTracts, Inc. second generation UroLift system, which is expected to
launch in the mid of 2018.
Some of the other key players providing products for BPH procedures in the
U.S. include NxThera, Inc., Boston Scientific Corporation, Urologix, LLC.,
Convergent Laser Technologies.
US Benign Prostatic Hyperplasia (BPH)
Download report sample at:
For information regarding permissions and other queries
Kindly write to:
[email protected]
US/Canada Toll-Free: 1-888-778-7886